Title: | Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601 |
Authors: | Akie, Kenji Browse this author |
Oizumi, Satoshi Browse this author →KAKEN DB |
Ogura, Shigeaki Browse this author |
Shinagawa, Naofumi Browse this author |
Kikuchi, Eiki Browse this author |
Fukumoto, Shinichi Browse this author |
Harada, Masao Browse this author |
Kinoshita, Ichiro Browse this author |
Kojima, Tetsuya Browse this author |
Harada, Toshiyuki Browse this author |
Fujita, Yuka Browse this author |
Ohsaki, Yoshinobu Browse this author |
Dosaka-Akita, Hirotoshi Browse this author |
Isobe, Hiroshi Browse this author |
Nishimura, Masaharu Browse this author |
Keywords: | Irinotecan |
S-1 |
Chemotherapy |
Nonplatinum regimens |
Non-small cell lung cancer |
phase II |
Issue Date: | Oct-2011 |
Publisher: | Karger |
Journal Title: | Oncology |
Volume: | 81 |
Issue: | 2 |
Start Page: | 84 |
End Page: | 90 |
Publisher DOI: | 10.1159/000331681 |
Abstract: | Objective: Platinum-free regimens can represent an alternative for advanced non-small cell lung cancer (NSCLC) if similar efficacy is provided with better tolerability. This study evaluated the efficacy and safety of combined irinotecan and S-1 for chemotherapy-naïve advanced NSCLC. Methods: Chemotherapy consisted of 4-week cycles of intravenous irinotecan (100 mg/m2, days 1 and 15) and oral S-1 (80 mg/m2, days 1-14). The primary endpoint was response rate, while secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety. Results: A total of 112 cycles was administered to 40 patients (median, 3 cycles; range 1-6 cycles). Twelve patients showed partial response (PR) and 17 patients exhibited stable disease (SD), representing a response rate of 30% and a disease control rate of 72.5%. Median survival time and median PFS were 16.1 months and 4.8 months, respectively. Hematological toxicities of grade 3 or 4 were neutropenia (32.5%) and anemia (5.0%). The most common non-hematological toxicities of grade 3 or 4 included diarrhea (15.0%) and anorexia (17.5%). Patients homo- or heterozygous for UGTA1A*6 tended to show a higher incidence of grade 3 diarrhea (p = 0.055). Conclusion: The combination of irinotecan and S-1 offers good efficacy and tolerability for previously untreated advanced NSCLC. |
Rights: | © 2011 S. Karger AG, Basel |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/47435 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|